Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lyell Immunopharma, Inc. (LYEL : NSDQ)

• Company Description    Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 300

• Price / Volume Information    Yesterday's Closing Price: $13.30 Daily Weekly Monthly 20 Day Moving Average: 23,871 shares Shares Outstanding: 19.21 (millions) Market Capitalization: $255.51 (millions) Beta: -0.19 52 Week High: $32.00 52 Week Low: $7.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 23.61% 21.37% 12 Week 38.83% 26.05% Year To Date 3.91% -7.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 HASKINS WAY - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-695-0677 fax: - erose@lyell.com http://www.lyell.com

• General Corporate Information    Officers Lynn Seely - Chief Executive Officer and President Richard D. Klausner - Chairman Charles Newton - Chief Financial Officer Otis Brawley - Director Catherine Friedman - Director Peer Information Lyell Immunopharma, Inc. (GSAC) Lyell Immunopharma, Inc. (CASI) Lyell Immunopharma, Inc. (ALCD.) Lyell Immunopharma, Inc. (OMNN) Lyell Immunopharma, Inc. (CGPI.) Lyell Immunopharma, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 55083R203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 19.21 Most Recent Split Date: 6.00 (0.05:1) Beta: -0.19 Market Capitalization: $255.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.26 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-13.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.69 Price/Cash Flow: - Price / Sales: 4,258.44 EPS Growth vs. Year Ago Period: 19.72% vs. Previous Quarter: 19.72% Sales Growth vs. Year Ago Period: -38.46% vs. Previous Quarter: 14.29% ROE 06/30/25 - -85.58 03/31/25 - -73.66 12/31/24 - -65.86 ROA 06/30/25 - -68.85 03/31/25 - -60.99 12/31/24 - -55.81 Current Ratio 06/30/25 - 7.65 03/31/25 - 7.49 12/31/24 - 7.06 Quick Ratio 06/30/25 - 7.65 03/31/25 - 7.49 12/31/24 - 7.06 Operating Margin 06/30/25 - -552,328.31 03/31/25 - -514,649.22 12/31/24 - -562,285.19 Net Margin 06/30/25 - -552,328.31 03/31/25 - -514,649.22 12/31/24 - -562,285.19 Pre-Tax Margin 06/30/25 - -552,328.31 03/31/25 - -514,649.16 12/31/24 - -562,285.19 Book Value 06/30/25 - 19.34 03/31/25 - 22.79 12/31/24 - 26.21 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©